Posters

      Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Events: Translating Basic Science into Clinical Benefit

      Pater, C.; Haziza, C.; Elamin, A.; Pouly, S.; de La Bourdonnaye, G.; Tran, C. T.; Lüdicke, F.

      Conference date
      Feb 18, 2019
      Conference name
      Cardiology Update 2019
      Link to more information
      Topic
      Summary

      Introduction: Cigarette smoke (CS) is causally linked to the development of cardiovascular disease (CVD) through different pathophysiologic pathways, which include endothelial injury and dysfunction, oxidative stress, a procoagulatory status, inflammation, and an abnormal lipid profile, all factors contributing to the development of atherosclerosis. Tobacco harm reduction, by substituting cigarettes with less harmful products, is a complementary approach to current strategies for smokers who would otherwise continue to smoke. The Tobacco Heating System (THS) 2.2 is a novel tobacco product that heats tobacco instead of burning it, never allowing the temperature to exceed 350°C, thereby preventing the combustion process from taking place and producing substantially lower levels of toxicants compared with CS. Method: Our assessment program aims to demonstrate that switching to THS has the potential to reduce the risk of smoking-related diseases versus continued smoking. The program includes in vitro/in vivo toxicology testing methods that follow OECD guidelines, Good Laboratory Practice, and a systems toxicology approach as well as a randomized, controlled clinical studies following the principles of Good Clinical Practice. Results: The results of the THS translational assessment program demonstrated that cardiovascular toxicants are reduced by more than 92% in THS aerosol versus CS and that THS aerosol contains no solid carbon-based nanoparticles. The effects of THS aerosol on the adhesion of monocytic cells to human coronary endothelial cells in vitro are significantly reduced. Switching to THS halted the progression of CS-induced atherosclerotic changes in ApoE-/- mice in in vivo studies. Clinical risk endpoints (CRE) linked to the development of smoking-related diseases were analyzed following a six-month randomized, controlled clinical study with THS that demonstrated a consistent improvement of CREs in different pathophysiologic pathways leading to atherosclerosis. Conclusion: The evidence available to date indicates that switching to THS has the potential to reduce the risk of smoking-related diseases, such as CVD. As a next step, we will complement the THS assessment program with health outcome studies intended to further support the clinical benefits of switching to THS as compared with continuous smoking.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.